GlassScriptPhysician profile
Beverly A Anderson
NPI 1417941121
$5,018.84
in general payments reported to CMS, 2019-2025
17 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what 86% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
See the full distribution for Psychiatric/Mental Health, Adult (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,692 · 2022: $945 · 2023: $743 · 2024: $595 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,381.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $1,282.68 | 2021-2025 | Rexulti, Brintellix |
| Abbvie INC. | $1,075.15 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $587.31 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $449.32 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $278.83 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $218.55 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $187.81 | 2024-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $169.81 | 2021-2022 | |
| Gilead Sciences, INC. | $123.16 | 2025 | Epclusa |
| Janssen Pharmaceuticals, INC | $118.90 | 2025 | Spravato |
| Neuronetics, INC. | $107.80 | 2023 | Neurostar Tms Therapy System |
| Vanda Pharmaceuticals INC. | $104.18 | 2025 | Fanapt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $97.16 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $94.18 | 2024 | Cobenfy |
| Corium, LLC | $86.90 | 2022-2024 | Azstarys |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $23.01 | 2025 | Zurzuvae |
| Ibsa Pharma INC. | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.